{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:13:26Z","timestamp":1793844806089,"version":"4.6.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["24CDA1272533"],"award-info":[{"award-number":["24CDA1272533"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","award":["Janice Wiesman Young Investigator Grant"],"award-info":[{"award-number":["Janice Wiesman Young Investigator Grant"]}],"id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive condition for which disease-modifying therapies are increasingly available. However, limited research has explored the patient experience with ATTR-CM and its impact on quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-center qualitative study, we conducted semi-structured interviews with ten participants (either with ATTR-CM or at-risk family members). At-risk family members were defined as asymptomatic individuals with a clinically actionable TTR variant that were identified through cascade genetic testing. Interviews were recorded, transcribed, and analyzed using a hybrid deductive and inductive approach. Two independent experts assessed participants\u2019 knowledge of ATTR-CM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four exploratory themes emerged regarding the ATTR-CM patient journey. Participants demonstrated moderate to excellent knowledge of disease and an appropriate level of confidence. Diagnostic delays were a major source of frustration and were largely attributed to limited knowledge among non-specialist providers. While these providers often recognized that something was wrong, they struggled with appropriate diagnostic work-up and timely specialist referrals. Patients also noted disparities in ATTR-CM care based on geography, race, and socioeconomic status. Reactions to support groups were mixed, with concerns about re-traumatization being most prominent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This qualitative study explores aspects of the ATTR-CM patient experience not captured through conventional clinical pathways. Diagnostic delays appeared to be driven by non-specialist provider knowledge gaps and systemic disparities in access to specialized care. These preliminary insights may inform the design of multidisciplinary care models that better reflect patient needs and priorities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-025-05282-7","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:00:03Z","timestamp":1762959603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Living with Transthyretin amyloid cardiomyopathy from a patient perspective"],"prefix":"10.1186","volume":"25","author":[{"given":"Quan M.","family":"Bui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"McCain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry A.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinnamon","family":"Bloss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borsika A.","family":"Rabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus A.","family":"Urey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"9","key":"5282_CR1","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2024.0442","volume":"331","author":"FL Ruberg","year":"2024","unstructured":"Ruberg FL, Maurer MS. Cardiac amyloidosis due to transthyretin protein: A review. JAMA. 2024;331(9):778\u201391.","journal-title":"JAMA"},{"issue":"11","key":"5282_CR2","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"C Writing","year":"2023","unstructured":"Writing C, Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, Dember LM, Frantz JG, Hershberger RE, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: A report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. 2023;81(11):1076\u2013126.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"5282_CR3","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1002\/ehf2.12793","volume":"7","author":"D Dang","year":"2020","unstructured":"Dang D, Fournier P, Cariou E, Huart A, Ribes D, Cintas P, Roussel M, Colombat M, Lavie-Badie Y, Carrie D, et al. Gateway and journey of patients with cardiac amyloidosis. ESC Heart Fail. 2020;7(5):2418\u201330.","journal-title":"ESC Heart Fail"},{"issue":"4","key":"5282_CR4","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1002\/ehf2.15311","volume":"12","author":"J Vogel","year":"2025","unstructured":"Vogel J, Jura S, Settelmeier S, Buehning F, Lerchner T, Carpinteiro A, Rassaf T, Michel L. Delays in diagnosis and treatment of ATTR cardiac amyloidosis: A real-world data analysis. ESC Heart Fail. 2025;12(4):2969\u201375.","journal-title":"ESC Heart Fail"},{"issue":"8","key":"5282_CR5","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.cardfail.2019.07.197","volume":"25","author":"I Lousada","year":"2019","unstructured":"Lousada I, Maurer MS, Warner M, Guthrie S, Gibbs S, Hegenbart U, Hsu K, Grogan M. Amyloidosis research consortium cardiac amyloidosis survey: results from patients with AL and ATTR amyloidosis and their caregivers. J Card Fail. 2019;25(8):S69.","journal-title":"J Card Fail"},{"issue":"9","key":"5282_CR6","doi-asserted-by":"publisher","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","volume":"12","author":"MS Maurer","year":"2019","unstructured":"Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, Grogan M, Kristen AV, Lousada I, Nativi-Nicolau J, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12(9):e006075.","journal-title":"Circ Heart Fail"},{"issue":"23","key":"5282_CR7","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","volume":"37","author":"T Damy","year":"2016","unstructured":"Damy T, Costes B, Hagege AA, Donal E, Eicher JC, Slama M, Guellich A, Rappeneau S, Gueffet JP, Logeart D, et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J. 2016;37(23):1826\u201334.","journal-title":"Eur Heart J"},{"issue":"12","key":"5282_CR8","doi-asserted-by":"publisher","first-page":"e014938","DOI":"10.1161\/CIRCIMAGING.122.014938","volume":"15","author":"EJ Rowin","year":"2022","unstructured":"Rowin EJ, Ruberg FL, Das G, Higgins D, Lipe WC, Bokhari N, Dehn M, Maron BJ, Maron MS. Identification of transthyretin cardiac amyloidosis among patients previously diagnosed with hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2022;15(12):e014938.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"38","key":"5282_CR9","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","volume":"38","author":"A Castano","year":"2017","unstructured":"Castano A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, Rubin J, Chiuzan C, Nazif T, Vahl T, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38(38):2879\u201387.","journal-title":"Eur Heart J"},{"issue":"6","key":"5282_CR10","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.jcmg.2019.10.015","volume":"13","author":"MB Musumeci","year":"2020","unstructured":"Musumeci MB, Cappelli F, Russo D, Tini G, Canepa M, Milandri A, Bonfiglioli R, Di Bella G, My F, Luigetti M, et al. Low sensitivity of bone scintigraphy in detecting Phe64Leu Mutation-Related transthyretin cardiac amyloidosis. JACC Cardiovasc Imaging. 2020;13(6):1314\u201321.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"5282_CR11","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/s13023-020-01633-z","volume":"15","author":"M Grandis","year":"2020","unstructured":"Grandis M, Obici L, Luigetti M, Briani C, Benedicenti F, Bisogni G, Canepa M, Cappelli F, Danesino C, Fabrizi GM, et al. Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus. Orphanet J Rare Dis. 2020;15(1):348.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"5282_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13023-021-01706-7","volume":"16","author":"D Rintell","year":"2021","unstructured":"Rintell D, Heath D, Braga Mendendez F, Cross E, Cross T, Knobel V, Gagnon B, Turtle C, Cohen A, Kalmykov E, et al. Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups. Orphanet J Rare Dis. 2021;16(1):70.","journal-title":"Orphanet J Rare Dis"},{"key":"5282_CR13","unstructured":"Creswell JW. Qualitative inquiry & research design: choosing among five approaches. Sage; 2013. 1-414."},{"key":"5282_CR14","doi-asserted-by":"crossref","unstructured":"Bui QM, Thompson JS, Berninger T, Hong KN, Anderson C, Allen LA, Adler ED, Urey MA, Bloss C, Rabin BA. Patient perspectives on genetic testing in transthyretin amyloid cardiomyopathy: framing the conversation to improve implementation. J Cardiac Fail - Intersections 2025. 1(1):17-25.","DOI":"10.1016\/j.yjcafi.2025.05.002"},{"key":"5282_CR15","unstructured":"Consortium AR. The Voice of the Patient. 2016."},{"issue":"Suppl 2","key":"5282_CR16","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.2967\/jnumed.122.264866","volume":"64","author":"S Dorbala","year":"2023","unstructured":"Dorbala S, Kijewski MF. Molecular imaging of systemic and cardiac amyloidosis: recent advances and focus on the future. J Nucl Med. 2023;64(Suppl 2):S20\u20138.","journal-title":"J Nucl Med"},{"key":"5282_CR17","doi-asserted-by":"crossref","unstructured":"Harmon DM, Mangold K, Suarez AB, Scott CG, Murphree DH, Malik A, Attia ZI, Lopez-Jimenez F, Friedman PA, Dispenzieri A et al. Postdevelopment Performance and Val idation of the Artificial Intelligence-Enhanced Electrocardiogram for Detection of Cardiac Amyloidosis. JACC Adv 2023, 2(8):1-11.","DOI":"10.1016\/j.jacadv.2023.100612"},{"issue":"1","key":"5282_CR18","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1038\/s41467-021-22877-8","volume":"12","author":"S Goto","year":"2021","unstructured":"Goto S, Mahara K, Beussink-Nelson L, Ikura H, Katsumata Y, Endo J, Gaggin HK, Shah SJ, Itabashi Y, MacRae CA, et al. Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms. Nat Commun. 2021;12(1):2726.","journal-title":"Nat Commun"},{"issue":"9","key":"5282_CR19","doi-asserted-by":"publisher","first-page":"100998","DOI":"10.1016\/j.jacadv.2024.100998","volume":"3","author":"A Vrudhula","year":"2024","unstructured":"Vrudhula A, Stern L, Cheng PC, Ricchiuto P, Daluwatte C, Witteles R, Patel J, Ouyang D. Impact of case and control selection on training artificial intelligence screening of cardiac amyloidosis. JACC Adv. 2024;3(9):100998.","journal-title":"JACC Adv"},{"issue":"4","key":"5282_CR20","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1016\/S2589-7500(23)00265-0","volume":"6","author":"CP Spielvogel","year":"2024","unstructured":"Spielvogel CP, Haberl D, Mascherbauer K, Ning J, Kluge K, Traub-Weidinger T, Davies RH, Pierce I, Patel K, Nakuz T, et al. Diagnosis and prognosis of abnormal cardiac scintigraphy uptake suggestive of cardiac amyloidosis using artificial intelligence: a retrospective, international, multicentre, cross-tracer development and validation study. Lancet Digit Health. 2024;6(4):e251\u201360.","journal-title":"Lancet Digit Health"},{"issue":"12","key":"5282_CR21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s11886-016-0802-1","volume":"18","author":"SJ Shah","year":"2016","unstructured":"Shah SJ, Cogswell R, Ryan JJ, Sharma K. How to develop and implement a specialized heart failure with preserved ejection fraction clinical program. Curr Cardiol Rep. 2016;18(12):122.","journal-title":"Curr Cardiol Rep"},{"issue":"9","key":"5282_CR22","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamacardio.2018.2093","volume":"3","author":"KM Alexander","year":"2018","unstructured":"Alexander KM, Orav J, Singh A, Jacob SA, Menon A, Padera RF, Kijewski MF, Liao R, Di Carli MF, Laubach JP, et al. Geographic disparities in reported US amyloidosis mortality from 1979 to 2015: potential underdetection of cardiac amyloidosis. JAMA Cardiol. 2018;3(9):865\u201370.","journal-title":"JAMA Cardiol"},{"key":"5282_CR23","doi-asserted-by":"publisher","first-page":"106740","DOI":"10.1016\/j.cct.2022.106740","volume":"116","author":"MD Kelsey","year":"2022","unstructured":"Kelsey MD, Patrick-Lake B, Abdulai R, Broedl UC, Brown A, Cohn E, Curtis LH, Komelasky C, Mbagwu M, Mensah GA, et al. Inclusion and diversity in clinical trials: actionable steps to drive lasting change. Contemp Clin Trials. 2022;116:106740.","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"5282_CR24","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/s12913-022-07816-7","volume":"22","author":"DM Thompson","year":"2022","unstructured":"Thompson DM, Booth L, Moore D, Mathers J. Peer support for people with chronic conditions: a systematic review of reviews. BMC Health Serv Res. 2022;22(1):427.","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"5282_CR25","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/fampra\/cmac004","volume":"39","author":"JH Joo","year":"2022","unstructured":"Joo JH, Bone L, Forte J, Kirley E, Lynch T, Aboumatar H. The benefits and challenges of established peer support programmes for patients, informal caregivers, and healthcare providers. Fam Pract. 2022;39(5):903\u201312.","journal-title":"Fam Pract"},{"issue":"1","key":"5282_CR26","doi-asserted-by":"publisher","first-page":"e022642","DOI":"10.1136\/bmjopen-2018-022642","volume":"9","author":"A Palant","year":"2019","unstructured":"Palant A, Himmel W. Are there also negative effects of social support? A qualitative study of patients with inflammatory bowel disease. BMJ Open. 2019;9(1):e022642.","journal-title":"BMJ Open"},{"issue":"4","key":"5282_CR27","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1177\/0194599817697030","volume":"156","author":"A Hu","year":"2017","unstructured":"Hu A. Reflections: the value of patient support groups. Otolaryngol Head Neck Surg. 2017;156(4):587\u20138.","journal-title":"Otolaryngol Head Neck Surg"},{"key":"5282_CR28","unstructured":"FDA. FDA Rare Disease Day Public Meeting. 2019."},{"issue":"3","key":"5282_CR29","doi-asserted-by":"publisher","first-page":"e0248240","DOI":"10.1371\/journal.pone.0248240","volume":"16","author":"CA McHorney","year":"2021","unstructured":"McHorney CA, Mansukhani SG, Anatchkova M, Taylor N, Wirtz HS, Abbasi S, Battle L, Desai NR, Globe G. The impact of heart failure on patients and caregivers: A qualitative study. PLoS ONE. 2021;16(3):e0248240.","journal-title":"PLoS ONE"},{"issue":"9","key":"5282_CR30","doi-asserted-by":"publisher","first-page":"e005828","DOI":"10.1161\/CIRCOUTCOMES.119.005828","volume":"12","author":"CK McIlvennan","year":"2019","unstructured":"McIlvennan CK, Morris MA, Guetterman TC, Matlock DD, Curry L. Qualitative methodology in cardiovascular outcomes research: A contemporary look. Circ Cardiovasc Qual Outcomes. 2019;12(9):e005828.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"5","key":"5282_CR31","doi-asserted-by":"publisher","first-page":"e010586","DOI":"10.1161\/CIRCOUTCOMES.124.010586","volume":"17","author":"LA Curry","year":"2024","unstructured":"Curry LA, Carter CR, Cherlin E, Toraman Turk S. Qualitative and mixed methods research in cardiovascular care: opportunities in the coming decades. Circ Cardiovasc Qual Outcomes. 2024;17(5):e010586.","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05282-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-05282-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05282-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:00:07Z","timestamp":1762959607000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-05282-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5282"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-05282-7","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the University of California, San Diego Human Research Protection Program (IRB #803384). All participants provided informed consent prior to participation in this study. This study adhered to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Larry Allen has received consulting fees from ACI Clinical, Quidel, and UpToDate, and grant funding from the NIH and PCORI. Marcus Urey has served on the advisory board and has received speaker fees from Alnylam, AstraZeneca, and BridgeBio. Marcus Urey also reports conflicts with Pfizer and has received research support for clinical trials from Ionis Pharmaceuticals and Alexion. None of the other authors have a financial relationship with a commercial entity that has an interest in the subject of the presented manuscript or other conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"802"}}